Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-Current Debt (2020 - 2025)

ImmunityBio (IBRX) has disclosed Non-Current Debt for 6 consecutive years, with $324.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 14.14% to $324.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $324.6 million through Dec 2025, up 14.14% year-over-year, with the annual reading at $324.6 million for FY2025, 14.14% up from the prior year.
  • Non-Current Debt for Q4 2025 was $324.6 million at ImmunityBio, up from $316.1 million in the prior quarter.
  • The five-year high for Non-Current Debt was $480.0 million in Q3 2023, with the low at $108.8 million in Q2 2024.
  • Average Non-Current Debt over 5 years is $280.4 million, with a median of $297.3 million recorded in 2021.
  • The sharpest move saw Non-Current Debt soared 506.48% in 2021, then tumbled 42.99% in 2024.
  • Over 5 years, Non-Current Debt stood at $303.2 million in 2021, then decreased by 5.1% to $287.8 million in 2022, then plummeted by 45.99% to $155.4 million in 2023, then skyrocketed by 83.0% to $284.4 million in 2024, then grew by 14.14% to $324.6 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $324.6 million, $316.1 million, and $307.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.